Blair William & Co. IL Has $3.19 Million Stock Holdings in CVS Health Co. (NYSE:CVS)

Blair William & Co. IL decreased its stake in CVS Health Co. (NYSE:CVS) by 34.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 70,996 shares of the pharmacy operator’s stock after selling 36,875 shares during the quarter. Blair William & Co. IL’s holdings in CVS Health were worth $3,187,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Arete Wealth Advisors LLC purchased a new stake in shares of CVS Health in the 3rd quarter valued at approximately $1,369,000. Edgestream Partners L.P. lifted its holdings in shares of CVS Health by 7.4% in the third quarter. Edgestream Partners L.P. now owns 20,734 shares of the pharmacy operator’s stock valued at $1,304,000 after purchasing an additional 1,437 shares in the last quarter. Erste Asset Management GmbH purchased a new position in shares of CVS Health during the third quarter valued at $6,109,000. Kestra Investment Management LLC acquired a new position in CVS Health during the third quarter valued at $341,000. Finally, TOMS Capital Investment Management LP purchased a new stake in CVS Health in the 3rd quarter worth about $121,987,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

NYSE CVS opened at $67.79 on Tuesday. The stock has a market capitalization of $85.46 billion, a PE ratio of 18.52, a P/E/G ratio of 0.98 and a beta of 0.54. The stock has a 50-day simple moving average of $62.42 and a 200 day simple moving average of $57.76. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $79.98.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Research analysts anticipate that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.92%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health’s dividend payout ratio is 72.68%.

Insider Activity

In related news, Director Michael F. Mahoney acquired 30,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were bought at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now owns 39,356 shares of the company’s stock, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.24% of the stock is owned by company insiders.

Analyst Ratings Changes

CVS has been the topic of a number of research reports. Wolfe Research upped their target price on CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, December 3rd. Cantor Fitzgerald raised shares of CVS Health from a “neutral” rating to an “overweight” rating in a research note on Wednesday, February 12th. UBS Group reduced their price objective on CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research report on Tuesday, February 11th. Finally, Leerink Partners raised CVS Health from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.39.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.